Onco-Innovations Limited (NEO:ONCO)
0.7500
+0.1000 (15.38%)
Jul 30, 2026, 12:56 PM EST
Onco-Innovations Revenue
In the fiscal year ending April 30, 2026, Onco-Innovations had annual revenue of 110.38K CAD with 69.06% growth. Onco-Innovations had revenue of 21.00K in the quarter ending April 30, 2026, a decrease of -67.84%.
Revenue
110.38K
Revenue Growth
+69.06%
P/S Ratio
351.80
Revenue / Employee
n/a
Employees
n/a
Market Cap
38.83M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2026 | 110.38K | 45.09K | 69.06% |
| Apr 30, 2025 | 65.29K | - | - |
| Apr 30, 2024 | - | - | - |
| Apr 30, 2023 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionOnco-Innovations News
- 1 day ago - Onco-Innovations Announces Initial Closing of Notional CAD$5 Million Performance-Based Funding Arrangement - TheNewswire
- 3 days ago - Onco-Innovations Announces Repricing of Previously Announced Performance-Based Funding Arrangement - TheNewswire
- 14 days ago - Onco-Innovations Initiates ADME Studies Supporting Development of ONC010 - TheNewswire
- 15 days ago - Onco-Innovations Announces Entry into Loan Agreements - TheNewswire
- 20 days ago - Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API - Accesswire
- 4 weeks ago - Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing - Accesswire
- 4 weeks ago - Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010 - Accesswire
- 4 weeks ago - Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010 - Accesswire